Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Also check out who works with our recent repeat client Numab
Company has also signed on Numab Therapeutics this year. Numab is a well-funded biotech operating in various therapy areas including oncology and boasts Daniel Vasella, the former CEO of Novartis, as its Chairman.
I think GSK as be the large pharma as CEO was business development there for 15yrs prior to becoming CEO in 2016, he has transformed PYC since 2016 hence why the 20yrs rubbish from share4 is laughable
Jim is taking us to profitability unlike the mgmt PRIOR to 2016
GSK acquire Sierra. SAR did deal with Sierra and PYC work(Ed) with SAR https://www.londonstockexchange.com/news-article/GSK/gsk-agrees-to-acquire-sierra-oncology-for-1-9bn/15410539
Both sellers informed market today via Form 3.1s
They sold Friday and reported today
10.34am and 1.36pm reported trades
Q: You mentioned Project Optimus in your last presentation. Could you please elaborate on this?
Well, just to remind everyone that Project Optimus is an FDA initiative aimed at helping companies developing drugs to focus more on the personalisation of dosing. So, although I don’t think it’s an initiative we would necessarily directly engage with, it’s certainly a clear signal that regulators are interested in how companies come to decisions about dosing in clinical trials. It’s certainly a key driver of the interest by our clients in engaging with mathematical modelling and specifically with us in the field of oncology to provide some weight behind and quantification of the decisions that they’re making on trial design, specifically in relation to dosing and scheduling decisions that have been made on a more heuristic basis in the past. If you go back 20 or 30 years in pharmaceutical industries, the way in which people calculated initial human doses was really just based on very simple algorithms, whereas now we’re able to bring to bear far more sophisticated tools and this is becoming an expectation. As a result I think the market for this sort of activity is going to continue to grow.
Pyc has tiny cash burn. . In the full year ended 30 June 2021 our net change in cash was a reduction of just ~£5k. In each of the last two full financial years we’ve maintained cash and equivalents of over £1m.
Hi matie, question on KEFI are they anywhere near profitable like PYC is? ?? are they invested in Ethiopian war zone asking for a friend ??
Q: Can we say how long we’ve been in discussion with the potential new big pharmaceutical client?
We’ve been in discussion with them for over 12 months, and that is common for big pharma clients. They take a long time to bring on board, but once you once you’ve got through all of their myriad procurement processes as well as the commercial negotiation around the contract then, with a following wind, they can turn out to be a client like Merck. So the opportunity is significant. It’s the sort of investment of time that, as a CEO or head of business development, you never mind making. As I said in our interims RNS, we are in in in advanced discussions with the company and we’ll say more as soon as we’re able to.
Q: Could you comment on your work or involvement with Merck KGaA?We’ve been engaged with Merck for many years, even before I arrived in the Company. As you will recall shortly after my arrival in the Company in around December 2017 we signed our first umbrella agreement with Merck where they aspired to spend at least €500,000 with us annually. I’m proud to say that we’ve done at least that every year since then. It’s not guaranteed and yet they’ve come back for more on a regular basis. Our close relationship has survived management changes and reorganisations and importantly our relationship with them today, I believe, is the best it’s ever been. Our work provides a key input to a number of important decisions they make relating to their active clinical programs and that makes me very proud. This relationship is a very real validation of our Virtual Tumour platform. Q: Is there any particular reason for the value of contracts remaining undisclosed?We can’t always disclose both the identity of our client and the value of the contract because they won’t let us. In my view, it’s more important for our shareholders and other stakeholders to understand who it is that we’re working with and what we’re doing rather than announce that we have a contract with an undisclosed pharmaceutical or biotech Company, because that sort of announcement never feels very satisfying and generally means that we can’t then really talk in any detail about what we’re doing with that client. I believe the value of being able to disclose the identity of clients is greater than the value of just disclosing the contract size. Where we’re required to disclose for reasons of compliance with regulations, then then we do so.
Q: What competitive advantage does Physiomics have?
That’s a great question. We have several. On the one hand, we are a specialist in oncology mathematical modelling, and there are few companies out there that can say that with their hand on heart. We have competitors that do mathematical modelling who tend to be generalists. We have competitors that focus on oncology, but they don’t tend to be specialists in modelling. So I believe the confluence of those two things is a position where we have a unique market opportunity. The second thing I would say is our people and our experience are really second to none. They work hard, they’re smart and they’re universally well respected by the clients that we take on. I also believe that we’re making genuinely important contributions to the R&D efforts of the clients that that we work with, and that has led to a significant boost in our reputation.
When I arrived at the Company 5-6 years ago, we were fairly little known other than amongst a small circle of clients that we’d been working with for a while. Now we’re getting referrals; people that we work with, talk to their friends and literally relatives sometimes, and we get phone calls from those individuals who may be working in in other companies. We’ve had several projects commissioned in this way, and this is extremely gratifying. I think it’s a real demonstration that what we do makes a difference and that our clients continue to value that.
Q: Please say a few words on the current pipeline?
The pipeline is genuinely the strongest it’s ever been. For the first time, we’ve really been able to quantify that by disclosing that we have contracted revenue of over £460,000 for this half that we’re in now. We’ve never been able to say that before. We’ve never had that degree of visibility for the next five months. And obviously that’s just the revenues that we have signed up at this point in time.
Above these contracted revenues in the pyramid of Business Development we have a number of contracts that are in discussion, one of which is with another big pharma Company. If we can clinch that one, that is another very exciting opportunity and could be a big step forward for the Company. But it’s not the only opportunity. We now have a more rigorous process for categorising the different opportunities thanks to our new BD lead. While this isn’t something that I can explain in a few words, I can assure you that at every stage within that BD funnel we now looking stronger than I think we ever have done before.
https://twitter.com/aiminvestor1978/status/1512310852925415426?s=21&t=5QXHZ7WS8EkypwLWGsXgUg
With more to come…. Tabula Rasa , Val201 and the large pharmaceutical client etc
Dec 2021
13th Further £300k with Merck for DNA repair work with more to follow
" there is no other company with Physiomics' experience in the field of DDR modelling"
23rd Follow up contract with Numab pharmaceutical
Feb 2022
Exploring more commercial deals with Tabula Rasa HealthCare now that PYC tech has been fully embedded
March 2022
New contract with USA client
Confirmation of record H1 revenues and record order book for H2 + discussions with new large pharma client
April 2022
New contract with French HQ client called Servier who are one of France's leading pharmaceutical companies with a truly global outlook
VAL updated on VAL201 2 weeks ago via RNS and expected before June 2022. Deal announcement any time soon :-)
Worth checking out #flx 5 million cap cyber tech play cashed up growing revs next cyber mover
Where are source that says 12th March for closure public comments?
Mms for some reason trying to keep lid on by delaying trades. Mine from earlier today not showing
https://twitter.com/aiminvestor1978/status/1362834094346956800?s=21
Do a vid now you idiot after you shafted shareholders pumping this
Over 200 in the fleet huge fuel savings